The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire
Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.
You may also be interested in...
The EU marketing application for aducanumab is heading for a rejection for Alzheimer’s disease, according to a “negative trend vote” at the CHMP disclosed by the drug’s sponsors.
The EMA’s likely rejection is no surprise for Biogen and Eisai, but adds to problems in the same week as Biogen’s R&D leader announced his departure.
The company insists it will reconsider the price of Aduhelm if the market turns out to be larger than Biogen anticipates, but big price reductions for branded drugs are rare.